^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Colorectal Cancer
    Drug:vudalimab (XmAb717) (PD1 inhibitor, CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

    Excerpt:
    ...Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or endometrial carcinoma; 8....
    Trial ID:
    DUET-2
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Xencor Press Release
    Title:

    Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

    Published date:
    05/13/2020
    Excerpt:
    ...phase 1 study evaluating XmAb®20717, a PD-1 x CTLA-4 bispecific antibody and Xencor’s first tumor microenvironment activator, in patients with advanced solid tumors (DUET-2). A patient with microsatellite instability-high (MSI-H) colorectal cancer, who had progressive disease after 10 months of treatment with pembrolizumab, and prior treatment with both nivolumab and ipilimumab, achieved stable disease, and continues on treatment at the 6 mg/kg dose level (cohort 5) at cycle 14 (392 days).